| Literature DB >> 35120179 |
Prabu Paramasivam1,2, Emmanuelle Meugnier3, Kuppan Gokulakrishnan4, Harish Ranjini1, Lisa R Staimez5, Mary Beth Weber5, K M Venkat Narayan6, Hubert Vidal3, Nikhil Tandon7, Dorairaj Prabhakaran7, Anjana Ranjit Mohan1, Viswanathan Mohan1, Sophie Rome3, Muthuswamy Balasubramanyam1,8.
Abstract
As blood-derived miRNAs (c-miRNAs) are modulated by exercise and nutrition, we postulated that they might be used to monitor the effects of a lifestyle intervention (LI) to prevent diabetes development. To challenge this hypothesis, obese Asian Indian pre-diabetic patients were submitted to diet modifications and physical activity for 4 months (LI group) and compared to a control group which was given recommendations only. We have considered 2 periods of time to analyze the data, i.e.; a first one to study the response to the intervention (4 months), and a second one post-intervention (8 months). At basal, 4 months and 8 months post-intervention the levels of 17 c-miRNAs were quantified, selected either for their relevance to the pathology or because they are known to be modulated by physical activity or diet. Their variations were correlated with variations of 25 metabolic and anthropometric parameters and cytokines. As expected, fasting-glycaemia, insulin-sensitivity, levels of exercise- and obesity-induced cytokines were ameliorated after 4 months. In addition, the levels of 4 miRNAs (i.e.; miR-128-3p, miR-374a-5p, miR-221-3p, and miR-133a-3p) were changed only in the LI group and were correlated with metabolic improvement (insulin sensitivity, cytokine levels, waist circumference and systolic blood pressure). However, 8 months post-intervention almost all ameliorated metabolic parameters declined indicating that the volunteers did not continue the protocol on their own. Surprisingly, the LI positive effects on c-miRNA levels were still detected, and were even more pronounced 8 months post-intervention. In parallel, MCP-1, involved in tissue infiltration by immune cells, and Il-6, adiponectin and irisin, which have anti-inflammatory effects, continued to be significantly and positively modified, 8 months post-intervention. These data demonstrated for the first time, that c-miRNA correlations with metabolic parameters and insulin sensitivity are in fact only indirect and likely associated with the level systemic inflammation. More generally speaking, this important result explains the high variability between the previous studies designed to identify specific c-miRNAs associated with the severity of insulin-resistance. The results of all these studies should take into account the level of inflammation of the patients. In addition, this finding could also explain why, whatever the pathology considered (i.e.; cancers, diabetes, neurodegenerative disorders, inflammatory diseases) the same subset of miRNAs is always found altered in the blood of patients vs healthy subjects, as these pathologies are all associated with the development of inflammation.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35120179 PMCID: PMC8815902 DOI: 10.1371/journal.pone.0263479
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Fig 1Summary of the protocol showing when metabolic/anthropometric data and c-miRNA/cytokines levels were quantified in serum from obese pre-diabetic Indian patients.
All the patients belong to the cohort D-CLIP [16].
Validation of the lifeStyle intervention protocol.
Anthropometrics and metabolic parameters of the subjects involved in the Standard Care (SC) or LifeStyle Intervention protocol (LI) determined at 4 months and at 8 months post-intervention.
| Standard Care (SC) | LifeStyle Intervention (LI) | SIgnificant delta (LI-SC) | ||||||
|---|---|---|---|---|---|---|---|---|
| Basal | 4 Mo | 12 Mo | Basal | 4 Mo | 12 Mo | 4 Mo | 12 Mo | |
| Weight (Kg) | 71.67 ± 8.61 | 70.28 ± 8.75 | 70.35 ± 8.38 | 72.07 ± 8.82 |
|
|
|
|
| BMI (Kg/m²) | 27.30 ± 2.88 |
|
| 27.9 ± 2.99 |
|
|
|
|
| Waist circumference (cm) | 93.13 ± 7.94 |
|
| 92 ± 9.2 |
|
| 0.0505 |
|
| hip-to-waist ratio | 4.69 ± 1.16 | 4.40 ± 0.85 |
| 4.79 ± 1.04 | 4.59 ± 0.87 |
| 0.7344 | 0.7419 |
| HOMA-IR | 3.64 ± 1.67 | 3.55 ± 1.46 | 3.12 ± 1.40 | 2.61 ± 1.16 |
|
|
| 0.2787 |
| Fasting Insulinemia (mg/dl) | 13.91 ± 5.99 | 14.03 ± 5.57 | 12.42 ± 5.51 | 10.37 ± 4.40 |
|
|
| 0.3784 |
| Fasting Glycaemia (mg/dl) | 104.93 ± 9.41 | 101.37 ± 10.29 | 101.03 ± 8.81 | 101.14 ± 7.77 |
|
| 0.2209 | 0.1330 |
| Hba1c (%) | 6.07 ± 0.53 | 6.02 ± 0.48 | 6.03 ± 0.48 | 5.80 ± 0.47 | 5.65 ± 0.34 | 5.69 ± 0.27 | 0.2927 | 0.5117 |
| Serum Cholesterol (mg/dl) | 180.87 ± 33.81 | 175.63 ± 32.29 | 169.87 ± 33.58 | 189.5 ± 31.19 | 174.95 ± 30.57 | 179.18 ± 32.44 | 0.2611 | 0.9256 |
| Serum Triglycerides (mg/dl) | 135.87 ± 50.97 | 128.2 ± 37.20 | 125.57 ± 42.99 | 156.04 ± 125.39 | 130.73 ± 81.09 | 133.68 ± 105.29 | 0.371 | 0.4326 |
| HDL cholesterol (mg/dl) | 39.7 ± 7 | 40.43 ± 5.81 | 40.8 ± 7.59 | 40.55 ± 6.69 | 38.82 ± 6.1 | 42.59 ± 7.83 | 0.065 | 0.5356 |
| LDL cholesterol (mg/dl) | 113.97 ± 31.71 | 109.53 ± 27.43 | 103.93 ± 31.13 | 117.74 ± 31.59 | 110.05 ± 25.67 | 109.87 ± 30.19 | 0.6752 | 0.8023 |
| VLDL cholesterol (mg/dl) | 27.2 ± 10.25 | 25.67 ± 7.42 | 25.13 ± 8.62 | 31.21 ± 25.08 | 26.08 ± 16.21 | 26.72 ± 21.12 | 0.3435 | 0.4157 |
| Bodyfat (%) | 30.43 ± 7.60 | 29.56 ± 7.84 | 31.10 ± 7.83 | 30.08 ± 7.09 | 206.85 ± 57.93 | 30.95 ± 8.38 | 0.5297 | 0.9077 |
| SBP (mmHg) | 122.6 ± 15.28 | 117.6 ± 12.27 | 121.07 ± 14.69 | 121.72 ± 13.57 |
| 118.14 ± 12.42 | 0.605 | 0.5019 |
| DBP (mmHg) | 72.83 ± 9.45 | 71.13 ± 7.10 | 70.5 ± 9.48 | 72.64 ± 9.08 | 68.5 ± 8.86 | 67.91 ± 7.89 | 0.2444 | 0.3745 |
| Irisin (ng/ml) | 39.52 ± 14.56 | 45.09 ± 18.72 | 51.22 ± 14.31 | 41.22 ± 16.81 |
|
|
|
|
| BDNF (ng/ml) | 813.49 ± 372.90 | 748.87 ± 342.66 | 919.66 ± 453.58 | 884.99 ± 298.31 | 1094.56 ± 265.75 |
|
| 0.1391 |
| Adiponectin (ng/ml) | 237.57 ± 116.64 | 280.67 ± 147.31 | 244.5 ± 110.62 | 242.71 ± 105.29 |
|
|
|
|
| IL6 (ng/ml) | 299.77 ± 61.52 | 272.43 ± 68.64 | 283.23 ± 82.39 | 306 ± 69.4 |
|
|
|
|
| PYY (ng/ml) | 13.28 ± 6.54 | 12.69 ± 6.44 | 12.39 ± 6.94 | 14.88 ± 5.99 |
|
|
| 0.3022 |
| TNF_alpha (ng/ml)v | 32.29 ± 13.98 | 28.69 ± 11.09 | 28.82 ± 7.68 | 29.51 ± 9.4 |
|
|
| 0.1737 |
| MCP (ng/ml) | 547.39 ± 183.02 | 474.8 ± 186.79. | 523.17 ± 191.76 | 539.91 ± 189.69 |
|
| 0.2788 |
|
| Leptin (ng/ml) | 1085.5 ± 205.20 | 1039.2 ± 185.32 | 1063.97 ± 236.53 | 1041.09 ± 210.62 |
|
| 0.0552 | 0.09 |
| Ghrelin (ng/ml) | 204.23 ± 62.56 | 219.43 ± 60.99 | 202.03 ± 71.18 | 206.85 ± 57.93 |
| 229.31 ± 97.55 | 0.3577 | 0.3347 |
Mo = Months. Data are adjusted to gender and age. Significant values calculated in each group independently are in bold (p<0.05 **;
p<0.01 ***). Significant variations (LI vs SC) = metabolic parameters which are affected by the LifeStyle Intervention protocol only (significant values are in bold). SBP = systolic blood pressure, DBP = Diastolic blood pressure.
Fig 2Expression of serum c-miRNAs significantly modulated by the 4 months LI protocol.
Data are expressed as delta of Ct values inversely correlation with their blood concentrations. Gender and age were taken into account for the analyses.
Variations of circulating miRNAs (ratios of Ct values) in serum from all subjects involved in the Standard Care (SC) or LifeStyle Intervention protocol (LI).
| Standard Care | LifeStyle Intervention | SIgnificant variations (LI-SC) | ||||||
|---|---|---|---|---|---|---|---|---|
| Basal | 4 Mo | 12 Mo | Basal | 4 Mo | 12 Mo | 4 Mo | 12 Mo | |
| miR-128-3p | 1.59 ± 1.36 |
| 2.78 ± 1.76 | 1.29 ± 0.98 |
|
|
|
|
| miR-133a-3p | 1.53 ± 1.64 | 1.20 ± 0.94 | 1.07 ± 1.66 | 1.47 ± 1.14 |
|
|
|
|
| miR-146a-3p | 1.99 ± 1.98 |
| 0.55 ± 1.09 | 2.02 ± 1.94 | 3.14 ± 3.44 |
|
|
|
| miR-423-5p | 1.69 ± 1.74 | 1.09 ± 0.94 | 0.96 ± 0.68 | 1.50 ± 1.25 |
| 1.69 ± 0.88 | 0.0076 |
|
| miR-374a-5p | 1.26 ± 0.81 | 1.90 ± 1.47 | 1.99 ± 1.16 | 1.12 ± 0.64 |
|
|
|
|
| miR-1-3p | 1.16 ± 0.63 |
| 0.86 ± 0.75 | 1.26 ± 0.73 | 1.93 ± 3.26 |
|
|
|
| let7d-3p | 1.55 ± 1.37 | 0.95 ± 1.01 | 1.20 ± 1.30 | 1.25 ± 0.83 | 1.47 ± 0.97 | 1.78 ± 1.37 | 0.0205 | 0.2308 |
| miR-126-3p | 1.33 ± 1.02 | 1.11 ± 0.41 | 1.68 ± 1.52 | 1.29 ± 0.81 | 1.68 ± 0.79 | 2.07 ± 1.53 | 0.0811 | 0.1139 |
| miR-21-5p | 1.37 ± 0.93 | 1.92 ± 1.19 | 1.87 ± 2.35 | 1.47 ± 1.09 | 0.97 ± 0.59 | 1 ± 0.55 | 0.0140 | 0.9947 |
| miR-222-3p | 2.02 ± 2.11 | 1.92 ± 1.89 | 1.91 ± 1.66 | 1.58 ± 1.47 | 0.75 ± 0.56 | 1.04 ± 0.71 | 0.1534 | 0.4090 |
| miR-221-3p | 1.39 ± 1.09 | 1.44 ± 1.25 | 1.18 ± 1.58 | 1.17 ± 0.64 | 0.79 ± 0.77 | 0.97 ± 0.47 |
| 0.4702 |
| miR-210-3p | 2.27 ± 2.29 | 2.92 ± 2.45 | 3.48 ± 4.05 | 1.86 ± 2.36 | 1.08 ± 1.12 | 1.87 ± 1.62 | 0.0055 | 0.6526 |
| miR-130b-3p | 1.15 ± 0.59 | 0.98 ± 0.82 | 1.44 ± 1.08 | 1.81 ± 2.97 | 0.84 ± 0.56 | 1.28 ± 0.77 | 0.8281 | 0.7087 |
| miR-29b | 1.50 ± 1.44 | 1.27 ± 1.05 | 1.58 ± 1.50 | 1.32 ± 1 | 0.95 ± 0.52 | 0.94 ± 0.43 | 0.6969 | 0.8244 |
| miR-29c | 1.32 ± 0.87 | 1.54 ± 1 | 1.18 ± 1.07 | 1.76 ± 1.66 | 2.15 ± 2.82 | 1.67 ± 1.67 | 0.4723 | 0.3892 |
Mo = Months. Data were adjusted for gender and age. Ct values are inversely correlated with seric miRNAs concentrations. Significant values calculated in each group independently are in bold (p<0.05 *;
p<0.01 ** (4 months vs Basal or 12months vs Basal)). Significant variations (delta LI vs delta SC) = list of miRNAs affected by the LifeStyle Intervention protocol only.
The significant regulation of miR-423-5p at 4 months was lost when the 8 subjects treated with metformin were removed from the LI group before analysis. The significant variation (delta LI vs delta SC) were lost for miR-21-5p when the 8 subjects treated with metformin were removed from the LI group before analysis.
Fig 3Spearman correlations between variations of c-miRNA levels and variations of metabolic parameters and cytokine concentrations.
As after months, 8 patients from the LI group received metformin, they were removed from the analysis.